{"id":13146,"date":"2023-06-06T05:00:00","date_gmt":"2023-06-06T09:00:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-invitee-a-participer-a-une-prochaine-conference-investisseur-4\/"},"modified":"2023-06-06T05:00:00","modified_gmt":"2023-06-06T09:00:00","slug":"dbv-technologies-invitee-a-participer-a-une-prochaine-conference-investisseur-4","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/dbv-technologies-invitee-a-participer-a-une-prochaine-conference-investisseur-4\/","title":{"rendered":"DBV Technologies invit\u00e9e \u00e0 participer \u00e0 une\u00a0prochaine Conf\u00e9rence Investisseur"},"content":{"rendered":"<div class=\"pr-date-globe\">June 06, 2023 17:00 ET<\/div>\n<p align=\"right\">Montrouge, France, le 6 juin (23&nbsp;:00 CET) 2023 <\/p>\n<p align=\"justify\"><strong>DBV Technologies invit\u00e9e \u00e0 participer \u00e0 une&nbsp;prochaine Conf\u00e9rence Investisseur<\/strong><\/p>\n<p align=\"justify\">DBV Technologies (Euronext : DBV &#8211; ISIN : FR0010417345 &#8211; Nasdaq Stock Market : DBVT), une soci\u00e9t\u00e9 biopharmaceutique au stade clinique, a annonc\u00e9 aujourd&rsquo;hui sa participation \u00e0 la 44\u00e8me conf\u00e9rence mondiale annuelle sur la sant\u00e9 organis\u00e9e par Goldman Sachs du 12 au 15 juin \u00e0 Dana Point, en Californie. Daniel Tass\u00e9, directeur g\u00e9n\u00e9ral, participera \u00e0 \u00ab&nbsp;Fireside Chat \u00bb le mercredi 14 juin \u00e0 10h00 PST (1h00 EST), ainsi qu&rsquo;\u00e0 des rencontres individuelles avec les investisseurs tout au long de la journ\u00e9e.<\/p>\n<p align=\"justify\">La pr\u00e9sentation sera retransmise en direct sur le site web de la soci\u00e9t\u00e9, dans la section Investisseurs et m\u00e9dias : <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X7-yoDbCotzefWxf_5NhJz9S7sDDCsvIOCUjIyYCNp450yW_mH5d3FC-7oEqXb5Sc4eVbh6-5GsczclTqDL7-RmcrOWmtM6e2qU9-mFqir83v9mqrBaBCxFF58fIA5j8Fj86_GEDFWOQEu9mZDviJoNXJp_Afvry6771G2qDmLxGLTVb2X81Offw0mkDobmejVIKNB0RQzb6kkN1yEc1Pg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"DBV Technologies - 1617085 (webcasts.com)\">DBV Technologies &#8211; 1617085 (webcasts.com)<\/a><\/p>\n<p align=\"justify\">L\u2019enregistrement sera \u00e9galement disponible pendant 90 jours apr\u00e8s l\u2019\u00e9v\u00e8nement&nbsp;sur le site internet de DBV Technologies.<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br \/><strong>A propos de DBV Technologies<\/strong><br \/>DBV&nbsp;Technologies d\u00e9veloppe Viaskin\u2122, une plateforme technologique exclusive exp\u00e9rimentale avec de larges applications potentielles en immunoth\u00e9rapie. Viaskin est bas\u00e9 sur l\u2019immunoth\u00e9rapie \u00e9picutan\u00e9e, ou EPIT\u2122, et constitue la m\u00e9thode de DBV&nbsp;Technologies pour d\u00e9livrer des compos\u00e9s biologiquement actifs au syst\u00e8me immunitaire \u00e0 travers la peau intacte. Avec cette nouvelle classe de produits candidats non invasifs, la Soci\u00e9t\u00e9 vise \u00e0 transformer en toute s\u00e9curit\u00e9 le traitement des patients souffrant d\u2019allergies alimentaires. Les programmes de DBV&nbsp;Technologies sur les allergies alimentaires comprennent des essais cliniques en cours sur Viaskin Peanut. Le si\u00e8ge mondial de DBV&nbsp;Technologies est situ\u00e9 \u00e0 Montrouge, en France, et ses op\u00e9rations nord-am\u00e9ricaines sont bas\u00e9es \u00e0 Basking Ridge, NJ. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment&nbsp;B d\u2019Euronext Paris (symbole&nbsp;: DBV, code ISIN&nbsp;: FR0010417345) et les ADS de la Soci\u00e9t\u00e9 (chacun repr\u00e9sentant une demi-action ordinaire) sont n\u00e9goci\u00e9s sur le Nasdaq Global Select Market (symbole&nbsp;: DBVT).<\/p>\n<p align=\"justify\"><strong>Contact Investisseurs <\/strong><br \/>Katie Matthews<br \/>+1&nbsp;857-529-2563<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ujBVNw5iU-rqu5g2i6JvoQGM49bHsXvXRuE8GhJIsMIIvm9g1fsQPJLOCk2y2WSg49wQu-vldV31plbg2XRG1KQ7w-W6liLs0u_zjlAx7l7TCNVra2RLftvDFH-id-oZW1LnIijSx7ilgLgCp-Amyg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"katie.matthews@dbv-technologies.com\">katie.matthews@dbv-technologies.com<\/a><\/p>\n<p align=\"justify\"><strong>Contact<\/strong> <strong>M\u00e9dia<\/strong><br \/>Angela Marcucci<br \/>DBV Technologies<br \/>+1&nbsp;646-842-2393<\/p>\n<p align=\"justify\">angela.marcucci@dbv-technologies.com<\/p>\n<p align=\"justify\">Viaskin and EPIT are trademarks of DBV Technologies.<\/p>\n<\/p>\n<p id=\"gnw_attachments_section-header\">    <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=8IMv-gnpDEA2sZFJ_YDZRe_8-05CHbqmABqoMwXNhDToWBqsYFcC8XiQP1FPg7UVbB-ZqxLsm-i70H4tqbVJKizucRQlpJrLTwwplXxZQwYDeNDhr2eyIT76eZIlrbA6vTyk1dXlbElAWJ2D92Ygjf_SMCJLM3vfuK23sbFnEmY=\" title=\"version PDF\" rel=\"nofollow noopener\">version PDF<\/a>      <\/li>\n<\/ul>\n<p><img decoding=\"async\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/YTViM2ZiYzEtMmJhOS00M2NhLThiNGMtNzZlNzVkMzQ1MDIyLTEwMTExNTI=\/tiny\/DBV-Technologies-S-A-.png\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\">        <\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[],"class_list":["post-13146","press_releases","type-press_releases","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/13146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/13146\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=13146"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=13146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}